10-Q: Silence Therapeutics Q1 2026 Financials Show Reduced R&D Spend

Silence Therapeutics plc reported a net loss of $14.96 million for Q1 2026, with a significant decrease in R&D costs and a cash runway extending into 2028.

Summary

• Silence Therapeutics plc reported a net loss of $14.96 million for the three months ended March 31, 2026, a decrease from $28.53 million in the same period of 2025.
• Revenue increased to $0.42 million from $0.14 million in Q1 2025, primarily due to the AstraZeneca collaboration.
• Research and development costs significantly decreased by $11.7 million to $9.1 million, mainly due to reduced contracted development costs for zerlasiran Phase 3 readiness and lower headcount.
• General and administrative expenses also decreased by $0.7 million.
• The company's cash, cash equivalents, and short-term investments stood at $70.1 million as of March 31, 2026, which management believes is sufficient to fund operations into 2028.
• The company is seeking third-party partners for the further development of SLN548 and zerlasiran.
• AstraZeneca has decided not to pursue further development of SLN312 beyond Phase 1, returning global rights to Silence Therapeutics.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net loss, AstraZeneca's decision to discontinue SLN312 development, and the ongoing need for substantial future capital raises, despite a positive cash runway extension.

Positives

• Net loss decreased significantly by $13.57 million compared to the prior year's quarter.
• Revenue increased by $0.28 million, driven by the AstraZeneca collaboration.
• Research and development expenses were substantially reduced by $11.69 million, indicating improved cost management.
• General and administrative expenses decreased by $0.66 million.
• Cash and short-term investments of $70.1 million provide a projected runway into 2028, reducing immediate funding concerns.
• Divesiran's Phase 2 trial is fully enrolled with topline results anticipated in August 2026.
• Zerlasiran has received positive regulatory feedback for its Phase 3 cardiovascular outcomes study design.
• SLN548 and SLN365 are advancing with promising preclinical results.
• SLN098 shows potential for obesity treatment with deep and durable knockdown in nonhuman primates.

Negatives

• The company continues to incur significant net losses ($14.96 million in Q1 2026).
• AstraZeneca will not pursue further development of SLN312, requiring Silence Therapeutics to re-evaluate its development plans.
• The company will need to raise additional funding for clinical development activities beyond its current cash runway.
• Goodwill decreased by $0.26 million due to translation adjustments.

Risks

• The successful development of product candidates is highly uncertain and involves significant risks.
• Future funding requirements depend on numerous factors including clinical trial success, regulatory approvals, and market acceptance.
• Changes in U.K. R&D tax credit regimes could materially impact cash flow and financial performance.
• The company may be required to delay, reduce, or eliminate research and development programs if future funding is not obtained.
• AstraZeneca's decision not to proceed with SLN312 development creates uncertainty regarding its future.
• The company is subject to risks associated with clinical trial enrollment, patient drop-out rates, and competition.

Future Outlook

The company believes its current cash and cash equivalents and short-term investments of $70.1 million are sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2028. However, additional funding will be required for clinical development activities. Future funding may come from public or private financings, debt financing, or collaboration agreements, including potential future milestone payments.

Management Comments

• "Based on this evaluation, the Group believes that its current cash and cash equivalents and short-term investment as of March 31, 2026 are sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2028."
• "The Group will need to raise additional funding to fund its operating expenses and capital expenditure requirements in relation to its clinical development activities."
• "AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1. We will re-gain full development, manufacturing and commercialization rights globally to this clinical asset following Phase 1 and are evaluating plans for further clinical development."

Industry Context

StockSavvy.ai notes that Silence Therapeutics' Q1 2026 results reflect a common trend in the early-stage biotechnology sector, characterized by significant R&D investment, ongoing net losses, and a critical reliance on future funding and strategic partnerships. The reduction in R&D spend, while positive for short-term cash preservation, will be closely watched to ensure it does not impede pipeline progression. The company's focus on RNA therapeutics aligns with a growing area of pharmaceutical innovation, but competition and the high failure rate in drug development remain significant industry challenges.

Comparison to Industry Standards

• The net loss of $14.96 million for the quarter is substantial but not unusual for a clinical-stage biotechnology company. Many companies in this sector operate at a loss for extended periods while developing novel therapies.
• The reduction in R&D spending from $20.8 million to $9.1 million represents a significant cost-saving measure. While this improves the cash runway, it is important to compare this level of spending against industry benchmarks for companies at a similar stage of development and with similar pipeline assets. For instance, companies advancing Phase 2/3 assets often have R&D budgets in the tens or hundreds of millions of dollars annually.
• The cash runway extending into 2028 is a positive indicator, providing a buffer for continued operations. However, the need for future capital raises is standard for the industry, as late-stage clinical trials and commercialization are extremely capital-intensive.
• The collaboration with AstraZeneca, despite the setback with SLN312, is a common strategy in biotech to share development costs and leverage partner expertise. The terms of such collaborations, including upfront payments, milestones, and royalties, are typical for the industry.

Legal Proceedings

• The company is not party to any material legal proceedings at this time.

Related Party Transactions

• None.

Stakeholder Impact

• Shareholders: The continued net losses and the need for future capital raises may impact share value. AstraZeneca's decision on SLN312 could affect future potential returns.
• Employees: A reduction in headcount contributed to lower R&D costs, which could impact employee morale or future capacity.
• Creditors: The company's cash runway into 2028 suggests short-term solvency, but future funding needs are a consideration.
• Partners/Collaborators: AstraZeneca's decision on SLN312 impacts the collaboration's future direction and potential revenue streams for Silence Therapeutics.

Next Steps

• AstraZeneca will not pursue further development of SLN312 beyond Phase 1; Silence Therapeutics will re-gain full global rights and is evaluating plans for further clinical development.
• Topline results for the SANRECO Phase 2 trial for divesiran are anticipated in August 2026.
• Phase 1 data presentations for SLN312 are planned for medical and research congresses in 2026.
• Additional preclinical data for SLN365 is anticipated in the second quarter of 2026.
• Additional disease model data for SLN098 is anticipated in the second quarter of 2026.
• Seeking third-party partners for the initiation of clinical development for SLN548.
• Seeking a third-party partner for potential Phase 3 development and future commercialization of zerlasiran.

Key Dates

Recommendation

Silence Therapeutics presents a mixed picture. The extended cash runway and progress in some pipeline candidates (Divesiran, SLN098) are positive. However, AstraZeneca's decision to discontinue SLN312 development is a significant setback, and the company's reliance on future capital raises and the inherent risks in drug development warrant caution. A 'hold' recommendation reflects the balance between potential upside from the pipeline and the substantial risks and uncertainties.

Keywords

Silence Therapeutics, 10-Q, RNA therapeutics, siRNA, Divesiran, Zerlasiran, SLN312, AstraZeneca, clinical trials, biotechnology, financial results, R&D costs, net loss, cash runway